Final Height in Patients With CAH

Congenital Adrenal Hyperplasia Clinical Trial

Official title:

Final Height in Patients With Congenital Adrenal Hyperplasia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04293133
• Other study ID #: CAH
• Status: Not yet recruiting
• Start date: March 11, 2020
• Est. completion date: September 11, 2020

Study information

• Verified date: March 2020
• Source: Ain Shams University
• Contact: Mohammed Kamel
• Phone: +2001285819500
• Email: kamelasbour[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Congenital adrenal hyperplasia (CAH) is the most common inherited disorder in the adrenal gland in children. Growth is usually affected in CAH patients either due to the disease itself or treatment consequences.

Description:

CAH comprises a group of autosomal recessive disorders caused by a deficiency of one of five enzymes needed for the synthesis of cortisol leading to defect in cortisol synthesis with or without aldosterone deficiency and an increase in the production of adrenocorticotropic hormone through negative feedback.

The most common form is 21-hydroxylase deficiency (21OHD), which forms more than 90 % of the cases.

In classic CAH, 75% of the patients have the salt wasting (SW) and 25% have the non salt-wasting phenotype (NSW).There are no clinical signs at birth in male infants and in female patients, CAH is suspected shortly after birth if there is genital ambiguity, ranging from slight clitromegaly to complete masculinization with acceleration of growth and pubertal development.

The non-classic (late onset) form of CAH is a less severe form of 21OHD, and is diagnosed later in life.

Final height in early and late onset patients has been reported as diminished (Hauffa et al, 1997).This could be attributed to androgen excess or treatment with steroids. Androgen excess can occur at any age leading to accelerated growth, early epiphyseal closure and compromised final adult height.

Despite that all forms of CAH differ in their degree of enzymatic deficiency, they all represent a therapeutic challenge to pediatric endocrinologists attempting to optimize growth.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: September 11, 2020
• Est. primary completion date: August 11, 2020
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• Patients having a documented history of classical CAH.

Exclusion Criteria:

• Patients with non classical CAH.

• Patients treated with growth hormone.

• Chronic use of medications unrelated to CAH which may affect growth like immunosuppressive drugs like azathioprine and drugs that affect growth hormone release like octreotide, pegvisomant, bromocriptine and cabergoline.

• Other chronic diseases that may affect growth like heart disease, inflammatory bowel disease and renal disease.

• Other causes of adrenal insufficiency.

Related Conditions & MeSH terms

• Adrenal Hyperplasia, Congenital
• Adrenogenital Syndrome
• Congenital Adrenal Hyperplasia
• Hyperplasia

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

References & Publications (2)

Charmandari E, Brook CG, Hindmarsh PC. Classic congenital adrenal hyperplasia and puberty. Eur J Endocrinol. 2004 Nov;151 Suppl 3:U77-82. Review. — View Citation

Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child. 1995 Jul;73(1):25-9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Final height in patients with congenital adrenal hyperplasia	Target height(TH) will be calculated using the formula: [maternal height + paternal height - 13 cm for girls and + 13 cm for boys]/2	Baseline